Rob’s career has been driven by curiosity and passion for life sciences. Following a PhD in molecular biology, he joined the original Dutch-based Organon as a research scientist.

Now, 30 years of various roles within different pharmaceutical companies have gained him exciting experiences, ranging from target discovery to early clinical development, and, most recently, drug manufacturing.

Since the 2021 spin-off of the new Organon, with a clear mission in Women’s Health, he’s in the Oss-site leadership team. In that role he has been at the base of the new Pharma Delta alliance, initiated in Jan 2024.